OBJECTIVES: To evaluate the influence of IGFBP-3 methylation on recurrence in patients with stage II colorectal cancer (CRC) from 2 independent cohorts. BACKGROUND: The relationship between IGFBP-3 methylation in primary tumors (PTs) or lymph nodes (LNs) and risk of recurrence in patients with stage II CRC treated with surgery alone is unknown. METHODS: IGFBP-3 methylation of DNA from 115 PTs and 1641 LNs in patients with stage II CRC from 2 independent cohorts was analyzed. Forty patients developed recurrence, whereas 75 matched patients remained recurrence free for more than 2 years after surgery. Cox proportional hazard models were used to calculate hazard ratios (HRs) of recurrence, adjusted for patient and tumor characteristics. RESULTS: Methylation of IGFBP-3 in PTs was identified to be significantly associated with risk of recurrence in the training set. The signature was tested in a validation set and classified 40.7% of patients as high risk. Five-year recurrence-free survival rates were 76.4% and 58.3% for low- and high-risk patients, respectively, with an HR of 2.21 (95% confidence interval, 1.04-4.68; P = 0.039). In multivariate analysis, the signature remained the most significant prognostic factor, with an HR of 2.40 (95% confidence interval, 1.10-5.25; P = 0.029). A combined analysis of 1641 LNs from the 2 sets identified IGFBP-3 methylation in LNs was not associated with risk of recurrence. CONCLUSIONS: Detection of IGFBP-3 methylation in PTs, but not in LNs, provides a powerful tool for the identification of patients with stage II CRC at high risk of recurrence.
OBJECTIVES: To evaluate the influence of IGFBP-3 methylation on recurrence in patients with stage II colorectal cancer (CRC) from 2 independent cohorts. BACKGROUND: The relationship between IGFBP-3 methylation in primary tumors (PTs) or lymph nodes (LNs) and risk of recurrence in patients with stage II CRC treated with surgery alone is unknown. METHODS:IGFBP-3 methylation of DNA from 115 PTs and 1641 LNs in patients with stage II CRC from 2 independent cohorts was analyzed. Forty patients developed recurrence, whereas 75 matched patients remained recurrence free for more than 2 years after surgery. Cox proportional hazard models were used to calculate hazard ratios (HRs) of recurrence, adjusted for patient and tumor characteristics. RESULTS: Methylation of IGFBP-3 in PTs was identified to be significantly associated with risk of recurrence in the training set. The signature was tested in a validation set and classified 40.7% of patients as high risk. Five-year recurrence-free survival rates were 76.4% and 58.3% for low- and high-risk patients, respectively, with an HR of 2.21 (95% confidence interval, 1.04-4.68; P = 0.039). In multivariate analysis, the signature remained the most significant prognostic factor, with an HR of 2.40 (95% confidence interval, 1.10-5.25; P = 0.029). A combined analysis of 1641 LNs from the 2 sets identified IGFBP-3 methylation in LNs was not associated with risk of recurrence. CONCLUSIONS: Detection of IGFBP-3 methylation in PTs, but not in LNs, provides a powerful tool for the identification of patients with stage II CRC at high risk of recurrence.
Authors: O A Ogunbiyi; P J Goodfellow; K Herfarth; G Gagliardi; P E Swanson; E H Birnbaum; T E Read; J W Fleshman; I J Kodner; J F Moley Journal: J Clin Oncol Date: 1998-02 Impact factor: 44.544
Authors: Samuel B Ho; Ann Hyslop; Richard Albrecht; Amanda Jacobson; Michael Spencer; David A Rothenberger; Gloria A Niehans; John D'Cunha; Robert A Kratzke Journal: Clin Cancer Res Date: 2004-09-01 Impact factor: 12.531
Authors: Yixin Wang; Tim Jatkoe; Yi Zhang; Matthew G Mutch; Dmitri Talantov; John Jiang; Howard L McLeod; David Atkins Journal: J Clin Oncol Date: 2004-03-29 Impact factor: 44.544
Authors: Mary Jo Fackler; Megan McVeigh; Jyoti Mehrotra; Marissa A Blum; Julie Lange; Amanda Lapides; Elizabeth Garrett; Pedram Argani; Saraswati Sukumar Journal: Cancer Res Date: 2004-07-01 Impact factor: 12.701
Authors: Justin C Brown; Michael R Rickels; Andrea B Troxel; Babette S Zemel; Nevena Damjanov; Bonnie Ky; Andrew D Rhim; Anil K Rustgi; Kerry S Courneya; Kathryn H Schmitz Journal: Endocr Relat Cancer Date: 2017-10-10 Impact factor: 5.678
Authors: Muriel X G Draht; Danny Goudkade; Alexander Koch; Heike I Grabsch; Matty P Weijenberg; Manon van Engeland; Veerle Melotte; Kim M Smits Journal: Clin Epigenetics Date: 2018-03-14 Impact factor: 6.551
Authors: Elham Jafari; Ali Gheysarzadeh; Karim Mahnam; Rezvan Shahmohammadi; Amir Ansari; Hadi Bakhtyari; Mohammad Reza Mofid Journal: Res Pharm Sci Date: 2018-08
Authors: Brendan J Guercio; Sui Zhang; Fang-Shu Ou; Alan P Venook; Donna Niedzwiecki; Heinz-Josef Lenz; Federico Innocenti; Michael N Pollak; Andrew B Nixon; Brian C Mullen; Bert H O'Neil; James E Shaw; Blase N Polite; Al Bowen Benson; James N Atkins; Richard M Goldberg; Justin C Brown; Eileen M O'Reilly; Robert J Mayer; Charles D Blanke; Charles S Fuchs; Jeffrey A Meyerhardt Journal: JNCI Cancer Spectr Date: 2020-08-27